Desano Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Desano Pharma - overview
Established
1996
Location
Shanghai, -, China
Primary Industry
Pharmaceuticals
About
Founded in 1996 and based in Shanghai, China, Desano Pharma is a pharmaceutical company that focuses on the research and development of anticancer drugs. In 2014, the company established the National Anti-HIV Drug Engineering Technology Research Center. In 2022, it obtained the control rights of Pfizer and Merck's new crown oral drugs. Desano Pharma has five production bases in Shanghai, Jiangsu, and Jiangxi for pharmaceutical preparations, APIs, and intermediates that meet cGMP and EHS requirements.
The company's main products include antiviral drugs, steroid hormone drugs and nucleic acid drugs. Its products are applied to diseases such as AIDS and COVID-19.
Current Investors
Qiming Venture Partners, Greenwoods Asset Management, China International Capital Corporation
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceuticals
Website
www.desano.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.